Advertisement

XORTX Therapeutics Inc. XRTX

Set alert

Price alert · XRTX

All alert types
1.00 USD -0.03 -2.91%

At close · Oct 30

0.98 -0.02 -2.00%

After hours · Oct 30, 4:00 PM ET

Bid
1.00 × 2
Ask
1.08 × 1
0.945 Day range 1.11
0.92 52-week range 3.24
YTD
-64.41%
1 year
-68.15%
Open
1.01
Prev close
1.03
Mkt cap
1.82M
Vol
24.99K
Avg vol
722.75K
EPS
-2.61
P/E
0.00
Div yield
0.00%
More statistics
Low
0.945
High
1.11
Forward P/E
-0.67
Beta
-0.21
Short ratio
0.02
Inst. own
6.03%
Dividend
0.00
Ex-div date
50-d avg
1.37
200-d avg
2.14
1y target
0.00

2Y chart

Chart tools
Interval

Events in this range
  • Nov 14, 2024Earnings: -0.2; estimate 0; surprise —%
  • Apr 6, 2026Split: 1 for 5
Signals (98)
NameDateAgo
RSI: OversoldOct 19, 20261 week ago
MACD: Sell SignalOct 15, 20262 weeks ago
MACD: Buy SignalOct 12, 20262 weeks ago
MACD: Sell SignalOct 9, 20263 weeks ago
MACD: Buy SignalOct 7, 20263 weeks ago
SMA: BearishSep 14, 20261 month ago
SMA: BullishSep 11, 20261 month ago
SMA: BearishSep 10, 20261 month ago
MACD: Sell SignalSep 9, 20261 month ago
SMA: BearishSep 3, 20261 month ago
SMA: BullishSep 2, 20261 month ago
SMA: BearishAug 28, 20262 months ago
SMA: BullishAug 27, 20262 months ago
SMA: BullishAug 25, 20262 months ago
MACD: Buy SignalAug 25, 20262 months ago
MACD: Sell SignalAug 18, 20262 months ago
SMA: BearishAug 17, 20262 months ago
SMA: BearishAug 6, 20262 months ago
SMA: BullishAug 4, 20262 months ago
MACD: Buy SignalJul 16, 20263 months ago
MACD: Sell SignalJul 15, 20263 months ago
MACD: Buy SignalJun 25, 20264 months ago
SMA: BearishMay 28, 20265 months ago
SMA: BullishMay 27, 20265 months ago
SMA: BearishMay 21, 20265 months ago
SMA: BullishMay 20, 20265 months ago
SMA: BearishMay 19, 20265 months ago
SMA: BullishMay 15, 20265 months ago
SMA: BearishMay 13, 20265 months ago
MACD: Sell SignalMay 7, 20265 months ago
SMA: BullishApr 6, 20266 months ago
MACD: Buy SignalMar 31, 20267 months ago
MACD: Sell SignalMar 20, 20267 months ago
MACD: Buy SignalFeb 25, 20268 months ago
RSI: OversoldFeb 18, 20268 months ago
RSI: OversoldFeb 5, 20268 months ago
MACD: Sell SignalJan 22, 20269 months ago
SMA: BearishJan 14, 20269 months ago
SMA: BullishJan 13, 20269 months ago
SMA: BearishJan 8, 20269 months ago
SMA: BullishJan 5, 20269 months ago
MACD: Buy SignalJan 5, 20269 months ago
MACD: Sell SignalDec 22, 202510 months ago
MACD: Buy SignalNov 19, 202511 months ago
MACD: Sell SignalOct 21, 20251 year ago
SMA: BearishOct 20, 20251 year ago
SMA: BearishOct 20, 20251 year ago
SMA: BullishOct 17, 20251 year ago
RSI: OverboughtOct 17, 20251 year ago
SMA: BullishOct 6, 20251 year ago
MACD: Buy SignalOct 6, 20251 year ago
SMA: BearishOct 3, 20251 year ago
SMA: BearishSep 26, 20251 year ago
MACD: Sell SignalSep 26, 20251 year ago
SMA: BullishSep 15, 20251 year ago
SMA: BearishSep 11, 20251 year ago
SMA: BullishSep 9, 20251 year ago
MACD: Buy SignalAug 21, 20251 year ago
MACD: Sell SignalAug 20, 20251 year ago
SMA: BearishAug 15, 20251 year ago
SMA: BullishAug 12, 20251 year ago
MACD: Buy SignalAug 11, 20251 year ago
MACD: Sell SignalJul 25, 20251 year ago
SMA: BearishJul 23, 20251 year ago
SMA: BullishJul 21, 20251 year ago
SMA: BearishJul 18, 20251 year ago
SMA: BullishJul 17, 20251 year ago
SMA: BearishJul 14, 20251 year ago
SMA: BullishJul 11, 20251 year ago
SMA: BearishJul 3, 20251 year ago
SMA: BullishJul 2, 20251 year ago
MACD: Buy SignalJun 27, 20251 year ago
SMA: BearishMay 23, 20251 year ago
SMA: BullishMay 20, 20251 year ago
SMA: BearishMay 19, 20251 year ago
SMA: BullishMay 16, 20251 year ago
SMA: BearishMay 15, 20251 year ago
MACD: Sell SignalMay 9, 20251 year ago
SMA: BullishApr 22, 20251 year ago
SMA: BearishApr 21, 20251 year ago
SMA: BullishApr 17, 20251 year ago
MACD: Buy SignalApr 17, 20251 year ago
SMA: BearishApr 3, 20251 year ago
SMA: BullishApr 2, 20251 year ago
SMA: BearishApr 1, 20251 year ago
SMA: BullishMar 27, 20251 year ago
MACD: Sell SignalMar 27, 20251 year ago
SMA: BearishMar 25, 20251 year ago
SMA: BullishMar 19, 20251 year ago
SMA: BearishMar 17, 20251 year ago
SMA: BullishMar 14, 20251 year ago
SMA: BearishMar 5, 20251 year ago
SMA: BullishMar 4, 20251 year ago
SMA: BearishFeb 28, 20251 year ago
SMA: BullishFeb 27, 20251 year ago
MACD: Buy SignalFeb 10, 20251 year ago
MACD: Sell SignalJan 16, 20251 year ago
SMA: BearishJan 15, 20251 year ago

Key statistics

Market cap
3.61M
Enterprise value
744.15K
Trailing P/E
9.33
Forward P/E
-0.67
PEG ratio
0.00
Price / sales
0.00
Price / book
0.48
EPS (TTM)
0.12
Beta
-0.21
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
0.00%
Revenue (TTM)
0
Revenue growth
0.00%
Free cash flow
-1.85M
Total cash
3.08M
Total debt
83.71K
Return on equity
-29.36%
Shares outstanding
3.22M
Short % of float
0.07%
50-day average
1.37
200-day average
2.14

Analyst view

Consensus: none

Price target (mean) 0.00

Next earnings

Consensus EPS estimate 0.00.

Earnings history

Financials — quick view

All financials
XRTX Revenue — quarterly 0
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
XRTX Net income — quarterly -1.69M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
XRTX EPS — quarterly -1.05
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

XRTX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 14, 2024Sep 1, 20240.00-0.20——
Aug 14, 2024Jun 1, 20240.000.06——
May 15, 2024Mar 1, 20240.00-1.24——
Apr 2, 2024Dec 1, 20230.00-0.48——
Nov 14, 2023Sep 1, 20230.00-6.03——
Aug 14, 2023Jun 1, 20230.00-0.81——

About XORTX Therapeutics Inc.

XORTX Therapeutics Inc., a late stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, pre-diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, a program to treat acute kidney injury (AKI) associated with respiratory virus infection and associated health consequences; and XRX-225, a program for treatment of type 2 diabetic nephropathy. It has a collaboration and license agreements with the Icahn School of Medicine; and a license agreement with the University of Florida Research Foundation, Inc. The company is based in Alberta Beach, Canada.

Sector
Healthcare
Industry
Biotechnology
Country
Canada
Website
xortx.com

News

Your note

Sign in to keep a note on XRTX — it syncs with the Stock Master app.

Insider holders

XRTX insider holders
InsiderRelationLatest transactionDateShares held
Davidoff, Allen WarrenDirector of IssuerAcquisition or disposition in the public marketNov 10, 2022440,917
Keshri (Amar Deep)Senior Officer of IssuerAcquisition or disposition in the public marketDec 1, 20218,500
MacDonald (David)Senior Officer of IssuerOpening Balance-Initial SEDI ReportJan 19, 202220,000
Pratt (Raymond Dennis M.D.)Director of IssuerOpening Balance-Initial SEDI ReportJan 11, 20220

Institution ownership

XRTX institution ownership
Holder% heldSharesValueReported
UBS Group AG0.54%18,78021.03KSep 29, 2024
National Bank of Canada/FI0.10%3,4403.85KSep 29, 2024
Osaic Holdings Inc0.03%1,1531.29KSep 29, 2024
Royal Bank of Canada0.02%672752Sep 29, 2024
JP Morgan Chase & Company0.01%254284Sep 29, 2024
Clearstead Advisors, LLC0.01%277310Sep 29, 2024
Advertisement